Prothena (PRTA)
(Delayed Data from NSDQ)
$20.81 USD
+0.60 (2.97%)
Updated May 31, 2024 04:00 PM ET
After-Market: $20.78 -0.03 (-0.14%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Brokerage Reports
0 items in cart
Prothena Corporation plc [PRTA]
Reports for Purchase
Showing records 281 - 300 ( 331 total )
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
LIFE SCIENCES AND HEALTH CARE
Provider: WEDBUSH SECURITIES INC.
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Best Ideas List -- May 2014 Performance
Provider: WEDBUSH SECURITIES INC.
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Removing from the Best Ideas List Due to Analyst Departure
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Removing from the Best Ideas List Due to Analyst Departure
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Q1:14 Update - Over Sold on Negative Market Sentiment - NEOD001 Data Updates May Come Sooner Than Expected
Provider: WEDBUSH SECURITIES INC.
Analyst: MARAI C
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Deep and Rapid Responses Support NEOD001 Mechanism and are Inconsistent with Responses from Prior Therapy
Provider: WEDBUSH SECURITIES INC.
Analyst: MARAI C
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Deep and Rapid Responses Support NEOD001 Mechanism and are Inconsistent with Responses from Prior Therapy
Provider: WEDBUSH SECURITIES INC.
Analyst: MARAI C
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Best Ideas List -- April 2014 Performance
Provider: WEDBUSH SECURITIES INC.
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Data Taken Out of Context - Encouraging ORGAN Response Rate
Provider: WEDBUSH SECURITIES INC.
Analyst: MARAI C
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Adding to Best Ideas List; Exceptional Response Rate for NEOD001 in Amyloidosis
Provider: WEDBUSH SECURITIES INC.
Analyst: MARAI C
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of April 21
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Parkinson''s Progress, Amyloidosis Data Upcoming
Provider: Roth Capital Partners, Inc.
Analyst: HAZLETT R
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
First Patient Dosed in Phase I Trial of PRX002 in Healthy Volunteers - Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: MARAI C
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
First Patient Dosed in Phase I Trial of PRX002 in Healthy Volunteers - Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: MARAI C
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.